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1. Introduction
Helicobacter pylori  ubiquitously infects the human gastric mucosa since time immemorial,
predictably  before  the  man’s  diaspora  out  of  East  Africa  around  58,000  years  ago  [1].
Colonization  may  have  been  somehow  beneficial  for  human  carriers,  allowing  the  co-
evolution  of  this  gram-negative  bacterium and  its  host  over  the  centuries.  Yet,  at  least
nowadays  [2],  this  may  not  be  a  peaceful  association,  with  infection  almost  invariably
causing an acute host  immune response.  However,  in a fully adapted manner,  H. pylori
avoids recognition and, thus, clearance, by the host immune system, with both infection
and the consequent gastritis persisting throughout the patients’ life. The clinical outcome
of  this  persistence  is  dependent  on  a  sophisticated  crosstalk  between  the  host  and  the
pathogen. If often asymptomatic, the H. pylori-associated non-ulcer dyspepsia is clearly the
strongest aetiological factor for severe gastric diseases that will develop late in adult life in
a minority of infected patients, i.e., peptic ulcer disease, both gastric and duodenal ulcers,
and  gastric  cancer,  namely,  adenocarcinoma  and  mucosa  associated  lymphoid  tissue
(MALT) lymphoma (reviewed in [3]). Peptic ulcer disease rarely occurs soon after H. pylori
infection [4-8] that generally starts in childhood; this presumably reflects marked differen‐
ces in the virulence [9-16] and/or in the susceptibility of young patients [17-19].
This chapter, focussing on the paediatric population, seeks to explore: the prevalence of H.
pylori infection; the molecular mechanism used by H. pylori during colonization and infection;
the role of this bacterium in the development of peptic ulcer-related organic dyspepsia; and
the genetic/proteome profile of the H. pylori-strains associated with peptic ulcer disease.
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1.1. Prevalence of infection
H. pylori is one of the most common gastrointestinal bacterial infections among humans,
affecting more than 50% of the world's population [1,20]. Infection is usually acquired during the
first years of life in both developing and industrialized countries, with intra-familial spread playing
a central role in transmission of the infection [21,22]. The prevalence of H. pylori is markedly
variable between developing and developed countries, and even among individuals living in
the same country, varying according to ethnicity, place of birth and socioeconomic factors.
Besides geographic area, age is also significantly and independently associated with an
increase in H. pylori prevalence, a phenomenon known as birth cohort effect, which is a
progressive reduction of the infection rate in successive birth cohorts, due to the improvements
in general living conditions (reviewed in [23]). In less developed countries the infection rate
reaches almost 50% in very young children and more than 90% in adults, whereas in indus‐
trialized countries H. pylori infects 20-50% of adults and less than 10% of children, and has been
declining over time [23,24]. Indeed, the prevalence of H. pylori infection is showing a decreased
trend worldwide that is directly associated with an improvement in the socioeconomic status and
hygienic conditions of the populations.
Accordingly, in Europe and North America, the epidemiology of H. pylori infection in children has
changed in recent decades. Nowadays, low incidence rates are found in the northern and western
European countries, resulting in prevalence far below 10% in children and adolescents. In contrast, the
infection is still common in certain geographic areas such as southern or eastern Europe, Mexico, and
certain immigrant populations from South America, Africa, most Asian countries, and first-nation
(aboriginal) people in North America [25-27]. In Portugal with the worst scenario of Europe, the
prevalence of H. pylori infection is closer to the situation observed in developing countries,
reaching 80% among the adult population in their early nineties, and, more recently, varying
from approximately 20% in young children (less than 5 years old) to 50% in children 10 to 15
years old [28,29].
The absence of effective vaccines [30] and of efficient alternatives to antibiotics [31-34] renders
difficult the worldwide prevention of H. pylori infection-associated diseases through massive
eradication of the bacterium. The current antibiotic therapy against H. pylori infection fails in
about 20% of the patients; depending on the therapeutic schema and strain resistance pattern,
the failure rate may reach 70%. Antibiotic resistance, mainly to clarithromycin, is the major
factor affecting the efficacy of standard triple therapy of H. pylori infection (co-administration
of two antibiotics and a proton pump inhibitor or ranitidine bismuth for seven to ten days). In
fact, the resistance rates to this and other second line antibiotics, such as the fluoroquinolones,
are increasing in many geographical areas [34-36].
Several studies reveal a similar or higher resistance rate to clarithromycin among paediatric
isolates as compared to those obtained from adults, especially in southern European countries,
reflecting the recognized overuse of macrolides in children in these countries [31,34,37,38]. As
an example, Portugal displays one of the highest rates of H. pylori primary resistance to
clarithromycin in Europe, similarly high in children as among adults (≈33%) [34]. Moreover,
resistance to second line antibiotics has rapidly increased over the last decade and is a matter
of concern [31-34]. This places the research on disease-specific bacterial biomarkers and their
Dyspepsia - Advances in Understanding and Management70
associated molecular mechanisms as a top priority to define disease-risk and to target H.
pylori eradication in high-risk individuals. Ultimately, it may provide novel bacterial and/or
host’s therapeutic or vaccine targets.
1.2. Molecular mechanisms of H. pylori colonization and infection
1.2.1. Acid resistance and motility
In a fully adapted manner, during colonization and persistence, this neutralophile bacterium
resists gastric acidity mainly through its urease activity. Its urease enzyme, a Ni2+-containing
dodecameric protein of approximately 1100 kDa, composed of 12 small subunits, UreA (27
kDa), and 12 large subunits, UreB (62 kDa), catalyzes the hydrolysis of urea into ammonia and
carbon dioxide, buffering both the bacteria cytoplasm and periplasm [39]. Accounting for
5-10% of the total protein content, urease is one of the most abundant proteins in the H.
pylori proteome [16,30]. Probably due to the toxicity of ammonia, urease activity is known to
be dependent on low pH and/or Ni2+ concentration conditions [39,40], being essential for
bacteria survival only under acidic conditions. In the early stages of colonization, H. pylori
seeks parts of the stomach with higher pH, such as the antrum (the distal part of the stomach).
Indeed, this bacterium uses the pH gradient as chemotactic signal to achieve regions of neutral
pH, since its spatial orientation is lost in the absence of the mucus pH gradient [41]. Thus, the
acid-producing parietal cells may protect the corpus region from initial invasion.
Efficient colonization of the gastric niche by H. pylori is also dependent on how fast it escapes
from the lumen of the stomach and reaches the mucus layer, avoiding elimination by gastric
peristalsis [42]. Its helical shape and the two to six polar, sheathed flagella provide swimming
abilities. According to a longstanding theory [43], the helical shape allows H. pylori to have a
corkscrew motion which, although not being essential for motility, enhances its ability to swim
through the viscous mucus layer. The machinery that gives rise to the spiral shape of this
bacterium remains largely unknown, but seems dependent on the coordinated action of
multiple proteins in a shape-generating pathway that leads to the relaxation of the peptido‐
glycan crosslinking [44]. Flagella are, however, essential for H. pylori motility. Indeed, aflagel‐
lated strains (obtained by elimination of both flaA and flaB, genes encoding the two major
components of flagellar filament, flagellins A and B) [45], as well as strains presenting non-
functional flagella (in knockout motB models lacking the gene that encodes the MotB flagellar
motor protein), are non-motile [42]. Such mutants are able to establish only transient coloni‐
zation in animal models [42,46]. Moreover, lower-motility strains are long known to induce
in vitro reduced inflammation levels, when compared to higher motility strains [47]. Once in
the mucus layer of the stomach, H. pylori resides here thereafter, either freely swimming [43]
or attached to host’s extracellular mucins [41], getting closer to the host’s gastric epithelial
surface whenever necessary. Occasionally H. pylori also can be internalized, entering the gastric
epithelial cells [48]. Invasion beyond the epithelial layer is, however, is a rare event.
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1.2.2. Bacterial Adherence
In the human stomach, the vast majority of H. pylori cells exist in their motile form within the
mucus layer lining; only a small portion (≈30%) are adherent to the surfaces of epithelial cells
[41]. Nevertheless, adherence to the gastric epithelium is important for the ability of H. pylori
to cause disease because this intimate attachment facilitates: 1) persistence, by preventing the
bacteria from being eliminated from the stomach through mucus turnover and gastric
peristalsis, and also by enabling the bacteria to replicate; 2) evasion from the human immune
system; 3) efficient delivery of the bacterial toxic proteins; and 4) acquiring nutrients released
from the damaged host cells.
H. pylori expresses a multitude of different adhesins. Best characterized is the blood group
antigen-binding adhesin (BabA), a ligand of ABO (of the blood group system) Lewis b (Leb)
antigens [49]. Sequence analyses reveals the existence of two allelic variants of babA, the babA1
and babA2 alleles, which are identical except for a 10 base pair insertion that results in a
translational initiation codon present in babA2 but absent in babA1, and of a highly homologous
gene, babB. Of these, only babA2 allele encodes a functional Leb adhesin [49]. BabA is not likely
to be essential for the colonization; BabA-expressing strains are no different in this step
compared to BabA-non-expressing strains [50]. BabA, being an adhesin, however likely plays
an important role in the induction of host inflammatory response. Indeed, babA2 allele is
clinically important, namely in a vacA/cagA-positive genetic background (two additional
important virulence factors discussed in section 1.2.3. of this chapter), which is associated with
peptic ulcer disease and gastric cancer [51]. BabA-expressing strains induces change in the
glycosylation pattern of the gastric mucosa of humans and animal models [50].
The second best characterized H. pylori adhesin is the sialic acid binding adhesin (SabA) which
mediates attachment to the inflammation-associated (sialylated Lewisx and Lewisa) antigens
[52]. In fact, gastric tissue inflammation and malignant transformation promote synthesis of
sialylated glycoconjugates, which are rare in healthy human stomachs [52, 53]. Accordingly,
high levels of sialylated glycoconjugates are found in H. pylori infected persons; these decrease
after eradication of the infection and resolution of the gastritis [54]. H. pylori can agglutinate
erythrocytes and neutrophils in vitro. The SabA adhesin is the hemagglutinin of H. pylori and
allows bacterial adherence to blood cells; this may result in systemic dissemination of the
pathogen [55]. Moreover, the binding of SabA to sialic acid carries neutrophil receptors,
essential for the nonopsonic activation of human neutrophils [56]. Neutrophils play a major
role in the epithelium injury, since these cells have direct toxic effects on the epithelial cells,
through the induction of an oxidative burst, with the release of reactive oxygen and nitrogen
species. Thus, the neutrophil activating capacity of SabA makes this protein an additional
virulence factor that is important in the pathogenesis of H. pylori infection.
The outer membrane inflammatory protein (OipA), a member of the Hop family of proteins,
is another H. pylori membrane protein with an active role in bacterial adherence, for which no
host receptors are known. Its encoding gene (oipA) is present in all H. pylori strains but it is
only expressed in those presenting the oipA “on” (i.e., functional) genotype. This is regulated
by slipped-strand mispairing, depending on the number of CT repeats in the 5’ region of the
gene [57]. OipA expression by H. pylori is associated with high bacterial densities, severe
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neutrophil infiltration and, ultimately, with peptic ulceration and gastric cancer [58,59].
Supporting the later association, the inactivation of oipA results in a reduced nuclear translo‐
cation of β-catenin, a known factor involved in the transcriptional up-regulation of genes
implicated in carcinogenesis [59].
1.2.3. Delivery and virulence factors
After adherence, H. pylori delivers its virulence factors into the cytoplasm of the host’s cells by
using a type IV secretion system (T4SS) and/or outer membrane vesicles. The genes encoding
the components of the T4SS, which is a syringe-like pilus protruding from the bacterial surface
used to inject virulence factors in host target cells’ cytoplasm, are located in the cag pathoge‐
nicity island (PAI) [60]. This is an approximately 40 kpb chromosomal insertion that is thought
to have been incorporated into the H. pylori genome by horizontal transfer from an unknown
source [61]. As a result, strains are heterogenic regarding the presence of this chromosomal
region, varying between those that contain the intact cag PAI to those that completely lack it.
For those lacking an intact T4SS, the delivery of their virulence factors is totally dependent on
the secretion of outer membrane vesicles with a still poorly known content; these are endocy‐
tosed by the host epithelial cells (reviewed in [62]).
Encoded by cytotoxin associated gene A, one of the 32 genes of the cag PAI region, CagA is
perhaps the most extensively studied translocated protein, the only known effector protein
injected by the T4SS. Once injected into cytoplasm of target cells, CagA interferes with several
host cell signalling cascades, ultimately inducing abnormal proliferation, cytoskeleton
rearrangements and inflammation through the release of cytokines, such as interleukin-1β
(IL-1β), IL-8 and tumour necrosis factor-α (TNF-α) (reviewed in [63]). There are two types of
clinical isolates regarding CagA: those producing this protein (cagA-positive H. pylori strains),
and the CagA-nonproducing strains (cagA-negative H. pylori strains). The cagA-positive strains
are considerably more virulent [60]. In Western countries, individuals carriers of cagA-positive
strains are thus at higher risk of peptic ulcer disease and/or gastric cancer [64,65], leading to
the classification of CagA as a bacterium-derived oncogenic protein [66]. In a not fully
undisclosed manner, the virulence of the cagA-positive strains is associated with the number
and the type of the phosphorylation motifs of the C-terminal variable region of the protein. Of
these motifs, defined as EPIYA (Glu-Pro-Ile-Tyr-Ala) A, B, C and D according to different
flanking amino acids, CagA protein nearly always possesses EIPYA-A and B segments,
followed by none, one, two or three C segments in Western-strains or a D segment in strains
of East Asian countries. The East Asian-type of CagA (ABD) is known to be more carcinogenic
than the Western-type; within the latter, the variants possessing multiple EPIYA-C motifs
(ABCC or ABCCC) are more virulent compared with those with a single segment (ABC)
(reviewed in [63]). Moreover, the association of CagA expression levels with polymorphisms
in the cagA promoter region may further contribute to differences in virulence among cagA-
positive strains and different disease-associated risks [67]. The virulence of the strain must also
be dependent on additional bacterial factors, since in East Asia most strains are cagA-positive
irrespective of the patient disease.
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The vacuolating toxin (VacA), another important virulence factor (reviewed in [68]), is
synthesized as a pro-toxin of ≈140 kDa, which contains a N-terminal signal sequence, a
passenger domain and C-terminal autotransporter domain. The passenger toxin domain (≈88
kDa) is cleaved and processed at some point during its secretion into the extracellular milieu
through the autotransporter that functions as a type V secretion system. This 88 kDa toxin is
further proteolytically cleaved, creating a N-terminal fragment of ≈33 kDa (p33) and a C-
terminal fragment of ≈55 kDa (p55) that remain non-covalently associated. Required for the
cytotoxic activity, the p33 subunit is postulated to be involved in the formation of anionic
membrane channels, while p55 subunit seems to mediate VacA binding to host cells (reviewed
in [68]). These functions are, however, highly dependent of the tridimensional structure of
both subunits [69,70]. Once secreted by the bacterial cells, VacA triggers various responses in
the host, resulting in the cellular vacuolation, pore formation in the cell membrane, disruption
of endosomal ⁄ lysosomal structure and function, apoptosis by toxin trafficking to mitochon‐
dria, and immunomodulation [71-73]. Virtually all H. pylori strains have a functional VacA.
However, the amount of toxin produced is related to the allelic variation of the encoding gene,
especially in its signal and middle regions (reviewed in [74]). Therefore, an association between
particular vacA allele types and peptic ulcer disease has been reported worldwide..
The ancient association between H. pylori and the modern humans [1,20] has determined the
abnormal high diversity in both their genetic background and the virulence observed among
strains. This generates complex scenario that creates difficulty in understanding the contribu‐
tion of each individual factor. Nevertheless, H. pylori strains presenting the association of these
two virulence factors, i.e., cagA-positive and vacA-toxigenic alleles, are considered to be more
virulent and thus more associated with severe organic dyspepsia inducers of a high production
of proinflammatory cytokines in the gastric mucosa and thus more severe non-ulcer dyspepsia.
Even so, these virulence factors do not appear to determine the overall pattern of gastro-
duodenal disease and a complex interplay between host bacterial factors and environment
seems to be involved in the development of gastric pathology [75].
1.2.4. Evasion
Upon colonization, H. pylori-infected patients experience a strong and complex immune
response in the gastric mucosa, both at the humoral and cellular levels; despite this response,
nevertheless the infection fails to clear. Therefore, in the absence of effective treatment,
infection becomes chronic, persists, and contributes to the immunopathology. The persistence
of infection throughout the life of its host is guaranteed by a set of molecular mechanisms used
by H. pylori to constantly evade the host immune response (reviewed in [76]). Bacterial mimicry
and genetic diversity play a central role in such successful strategies.
Mimicking the cell surfaces of the host, the lipopolysaccharide of the H. pylori cell wall is
relatively anergic compared to other gram-negative bacteria. In fact, the variable part of the
O-antigen chain of H. pylori lipopolysaccharide is composed of host-related Lewis antigens,
making it unrecognizable to the host immune system [77]. Therefore, this pathogen not only
binds to human Lewis antigens through BabA and SabA, but it also expresses Lewis-like
antigens facilitating the escape from the host immune system. Another ingenious camouflage
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used by H. pylori is the expression of proteins at its surface, which specifically bind to host-
secreted proteins, e.g., bacterial plasminogen-binding proteins (PgbA and PgbB). This allows
the bacterium to be coated with host proteins [78]. H. pylori also avoids immune recognition
through the in vitro and in vivo impairment of the expression of host’s specific heat shock
proteins, thus, inactivating both the innate and adaptive immune response [79].
Allelic diversification of its virulence factors encoding genes allows H. pylori to occupy
different microenvironments within the human stomach and to adapt to the varying conditions
in the niche over time. This is even more efficient, considering that the expression of different
variants of those genes may switch through mechanisms of phase variation. Indeed, several
in vitro studies have demonstrated that H. pylori Lewis-like antigens can undergo phase
variation (reviewed in [76]). Moreover, in animal models, persistent infection leads to the loss
of expression of babA. This occurs either by phase variation switching between an “on” and
an “off” status in a manner similar to that described for oipA (see section 1.2.2 of this chapter),
or by nonreciprocal gene conversion of babA to babB [80].
The existence of a small subpopulation of H. pylori within gastric epithelial cells (as briefly
discussed in section 1.2.1 of this chapter) may represent a sanctuary site that protects bacteria
against immune clearance [48].
1.3. Peptic Ulcer — Related organic dyspepsia in paediatrics, a rare event
Although rarely associated with severe forms of organic dyspepsia (namely peptic ulcer
disease) in the paediatric age group, H. pylori is clearly linked with acute gastric inflammation
in childhood and occurs frequently in children with dyspepsia [81]. This important association
gains relevance when considering that: a) gastric colonization by H. pylori occurring in
childhood and the consequent inflammation continues for life if left untreated; and b) this
lifelong persistence of inflammation after decades of infection is the main etiology for peptic
ulceration and/or cancer in adulthood. Moreover, some studies suggest a possible impact of
H. pylori-associated dyspepsia on anthropometry, as children with dyspepsia and H. pylori
infection are shorter and lighter than children with similar symptoms but no infection [82,83].
Evidence for the importance of H. pylori infection as a factor for dyspepsia in childhood comes
from H. pylori eradication resulting in a significant long-term improvement of dyspeptic
symptoms [84]. The symptoms of H. pylori-associated paediatric dyspepsia however do not
differ from those of non-infected dyspeptic children [85], raising questions about which
approach should be adopted in children with dyspepsia, in terms of H. pylori testing. According
to current guidelines for the management of H. pylori infection at pediatric age [86,87], the
primary goal of diagnostic interventions should be to determine the cause of the presenting
gastrointestinal symptoms (“scope and treat” strategy) and not just the presence of H. pylori
infection (“test and treat” strategy). Indeed, recurrent abdominal pain is not an indication for
a “test and treat” strategy concerning H. pylori infection in children, as evidence regarding the
association with H. pylori infection has been so far inconclusive (even in the presence of peptic
ulcer). Indeed, several studies using different noninvasive tests for H pylori infection compared
the prevalence of positive results in children with recurrent abdominal pain and controls and
found no significant difference in infection rates between cases and controls [88,89]. On the
Helicobacter pylori—Associated Dyspepsia in Paediatrics
http://dx.doi.org/10.5772/56551
75
other hand, pediatric studies are limited by the lack of a clear definition for recurrent abdomi‐
nal pain or by the use of nonspecific criteria for the diagnosis of chronic abdominal pain [90].
Nevertheless, in patients with persistent abdominal pain (after exclusion of other causes, such
as lactose intolerance, giardiasis, celiac disease, inflammatory bowel disease, among others) and/
or severe upper abdominal symptoms (namely suggesting peptic ulcer disease, such as
nocturnal pain), upper endoscopy with biopsy should be performed (diagnostic investigation
of choice). Furthermore, testing for H. pylori in children/adolescents should be considered if
there is a family history of gastric cancer and in children/adolescents with refractory iron
deficiency anemia, when no other cause is found. In these settings, when upper endoscopy is
performed, the presence of H. pylori should be systematically sought through histological
examination and, whenever feasible, culture and antibiotic susceptibility testing; treatment
should be offered in the presence of H. pylori positivity. Population screening for H. pylori in
asymptomatic children to prevent gastric cancer is not warranted. Although 13C-urea breath
testing is a validated noninvasive diagnostic test for H. pylori infection in children, a “test and
treat” strategy including this tool should not be indiscriminately adopted in clinical practice
at this age group, considering the fact that this test merely identifies H. pylori presence but not
necessarily the causality of symptoms. Noninvasive tests for H.pylori include different methods
for the detection of bacterial antigens in stool, detection of antibodies (IgG, IgA) against H.
pylori in serum, urine, and oral samples, and the 13C-UBT. In the paediatric group, both fecal
antigens determination and respiratory test are reliable to determine whether H pylori has been
eradicated or not after antibiotic treatment, while tests based on the detection of antibodies
against H pylori are considered not reliable for use in the clinical setting, but may be useful in
epidemiological studies [91].
Therefore, H. pylori infection in childhood differs from adults not only in terms of the prevalence of the
infection and a higher rate of antibiotic resistance, but also with respect to the complication rate, age-
specific problems with diagnostic tests and drugs, and the near-absence of gastric malignancies [92].
Nevertheless, H. pylori-associated peptic ulcer disease may also occur shortly after infection
in childhood [4-8]. This rare event may be due to more virulent strains [9-16], and/or more
predisposed subjects [17-19]. The two forms of H. pylori-associated peptic ulcers, i.e., gastric
ulcer and duodenal ulcers, are divergent in prevalence and physiopathology, but both cause
considerable patients’ morbidity entailing high annual costs of treatment [93].
1.3.1. Prevalence of H. pylori-associated gastric and duodenal ulcers in childhood
In general, about 10-15% of the H. pylori infected patients suffer from duodenal ulcer disease and 2-5%
with gastric ulcer and/or gastric cancer late in the adulthood [3]. Population-based studies in patients
with organic dyspepsia suggest that peptic ulcer disease related to H. pylori infection is decreasing in
prevalence in Western countries, along with a decrease in the prevalence of infection [94]. The former
should be a direct consequence of the second; with improved living standards, cohorts of children became
progressively less likely to acquire the organism and thus suffer from H. pylori-associated diseases.
Nevertheless, specific populations such as immigrants and rural communities may have a high
prevalence of infection and peptic ulcer disease; these individuals should be separately reviewed even in
areas where the general prevalence of H. pylori infection has declined below 15% [95]. Despite changing
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prevalence trends, H. pylori-induced gastritis causing mucosal ulceration either in the stomach
(gastric ulcer) or the proximal duodenum (duodenal ulcer) is a relatively uncommon event in
children, compared with adults [4-8]. In fact, during childhood, H. pylori is associated with
predominant antral gastritis or with pangastritis [96]. In children, few studies have yet investigated
the actual trend of H. pylori prevalence in peptic ulcer disease [5-8] and the available data are more
difficult to interpret, considering that the rates of peptic ulcer diagnosis depend also on the
clinical setting (endoscopy versus outpatient clinic or hospital admissions) [97,98]. For
example, in Italy the detection rate of ulcer disease was 7.8% out of an average of 180 paediatric
gastrointestinal endoscopies performed each year [99]. Similarly, a retrospective review (from
1998 to 2006) showed that 43 (6.9%) out of 619 Chinese children who underwent upper
endoscopy for investigation of upper gastrointestinal symptoms had peptic ulcer [7]; and
another retrospective study (from 2003 to 2006) have also reported a high incidence of peptic
ulcer (6.8%) in Israeli children submitted to upper endoscopy [100]. In Canada, however, the
approximate incidence of peptic ulcer was 1 case per 2,500 hospital admissions [92]. In a recent
large European multicenter study, including 1233 symptomatic children with H. pylori
infection, peptic ulcer disease was diagnosed in less than 5% of children younger than 12 years
of age and in ≈10% of teenagers [8]. Interestingly, other studies indicate a higher association
of H. pylori with peptic ulcer in adolescents than in younger children [100,101]. But, the
prevalence of H. pylori-positive ulcers in children also differs between countries and this is
not completely explained by the prevalence of the infection in the population studied. This is
easily demonstrated from data collected from January 2001 to December 2002 on 518 children
from the paediatric European register for treatment of H. pylori [5]. At endoscopy, 454 of those
patients had H. pylori-associated gastritis and 64 had a peptic ulcer (12.3%). This series also
included children from Russia, who had a significantly higher prevalence of peptic ulcer (35%)
compared to that of the remainder of European children (6.7%) [6]. In another report, school-
aged children with chronic abdominal complaints living in the rural area of Russia had a high
prevalence rate of H. pylori infection (80%) and also of peptic ulcer disease (24%) [102].
In adults, the prevalence of H. pylori infection is higher than 95% in duodenal ulcer cases and
around 60% to 80% in gastric ulcer cases [103]. This scenario is similar in children i.e. when H.
pylori-associated ulcers occur in children, duodenal ulceration is much more frequently
identified than gastric ulcers [104]. In fact, pooled analysis of early reports (from 1983 to 1994)
has demonstrated that the prevalence of H. pylori in children with duodenal ulcer was
relatively higher (ranging from 33% to 100%, with a median value of 92%), compared with
children with gastric ulcer (ranging from 11% to 75%, with a median value of 25%) [104]. A
more recent retrospective study (from 1995 to 2001) from Japan confirmed a very high
prevalence of H. pylori in antral gastritis and duodenal ulcer (98.5% and 83%, respectively),
also identifying H. pylori as a risk factor for the development of gastric ulcer although with a
lower prevalence of infection (less than 50%) [101]. Finally, in a Chinese study, it was reported
that among 43 Chinese children suffering with peptic ulcer disease, 37 had duodenal ulcer, of
which 21 were H. pylori positive, while only six had gastric ulcer, of which only two were
positive for the infection [7]. In summary, H. pylori infection is much more associated to
duodenal ulcer than to gastric ulcer, in both children and adults.
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The causative role of H. pylori in gastric ulcers in children and adolescents is, therefore, less
certain when compared to adults, possibly reflecting the fact that a large proportion of gastric
ulcers are secondary in nature in children. Characteristically, in children younger than 10 years
of age, peptic ulcers are usually due to noxious agents (such as corticosteroids and non-
steroidal anti-inflammatory drugs (NSAIDs)) or occur after major stresses (such as burns,
trauma, and systemic illness). In these settings, upper gastrointestinal tract haemorrhage,
vomiting and perforation are frequent presenting features. The ulcers tend not to recur after
healing. In older children and adolescents, the clinical presentation and natural history of
peptic ulcers are similar to that observed in adults, presenting as epigastric and nocturnal
abdominal pain and being usually associated with H. pylori infection [8,100,101]. In this setting,
even though the acute ulcer is likely to heal, the natural history is for ulcer recurrence.
Moreover, the complication rate of peptic ulceration is important. The estimated incidence of
peptic ulcer bleeding in the US paediatric population also has ranged from 0.5 to 4.4/100,000
individuals in 2008 [105].
These and other differences explain why some of the recommendations for adults may not
apply in children [87,96]. Few randomized, placebo-controlled treatment trials are available
in children for the different outcomes (gastritis or peptic ulcer), and often consist of only small
numbers of cases [86,106]. Clearly in children as in adults, successful eradication of H. pylori
markedly reduces the risk of ulcer recurrence [107-110]. Thus, there is general consensus
worldwide to treat H. pylori infection when there is endoscopic evidence of peptic ulceration.
Triple therapy is the treatment of choice in children for endoscopically proven duodenal ulcer
and histologically proven H. pylori antral gastritis [91, 96, 111, 112].
1.3.2. Differences in the physiopathology of H. pylori-associated gastric and duodenal ulcers
Peptic ulceration is a multifactorial disease ultimately explained by disequilibrium between
aggressive injurious factors and defensive gastroduodenal mucosa-protective factors, which
raises the vulnerability of this mucosa to luminal secretions. H. pylori infection is considered
the major causative factor for peptic ulceration. Nevertheless, there are other injurious
mechanisms jeopardizing the mucosal integrity: some viral infections (e.g. cytomegalovirus
and herpes simplex); drug-induced injury, particularly acetylsalicylic acid, NSAIDs and
chemotherapy; vascular disorders interfering with perfusion; major stresses; and syndromes
in which a marked overproduction of gastric acid occurs, as is the case of the Zollinger-Ellison
syndrome and, more commonly in children, antral G cell hyperplasia (also referred to as
pseudo-Zollinger Ellison syndrome) [113].
Although differing in their pathogenesis, both H. pylori-associated duodenal ulcers and gastric
ulcers are intimately related to changes in the acid production by the gastric mucosa [113,
114]. Indeed, H. pylori infection can result in increased, decreased or no overall change in the
level of gastric acid secretion. Duodenal ulcers arise on a background of H. pylori–induced
antral-predominant gastritis with sparing of the oxyntic mucosa, resulting in hypergastrine‐
mia and consequent high levels of acid production from the healthy gastric corpus following
meal or hormonal stimulation. In response to the excessive acid secretion, the duodenum
develops gastric metaplasia. This, unlike the normal duodenal mucosa, can be colonized by
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H. pylori with consequent inflammation and ulceration [113]. Eradication of the H. pylori
infection corrects the hypergastrinemia and decreases the basal acid secretory rate, heals any
peptic ulcer and ameliorates any symptoms of gastroesophageal reflux [115]. Conversely,
gastric ulcers are associated with H. pylori–induced pan- or corpus-predominant gastritis,
resulting in multifocal atrophy of acid-secreting mucosa and reduced acid secretion. These
ulcers usually arise at the junction of the antral and corpus mucosa, an area of intense inflam‐
mation [113]. Thus, the non-acidophilic nature of H. pylori (see section 1.2.1) explains how those
with low acid secretory capacity are more susceptible to spread of infection through the corpus
mucosa and to gastric ulceration. With their somewhat common pathobiology, gastric ulcer
disease precedes the development of gastric cancer [93,116,117]. Gastric and duodenal ulcers
have marked differences in their basis, placing them on opposite ends of disease spectrum. H.
pylori-induced duodenal ulcer conveys a lower risk of developing a gastric cancer [117]. But,
what makes it possible for H. pylori to be involved in both ends of disease spectrum? Although
the mechanisms are unclear, the infecting strain itself may play a crucial role on the diverging
point of this disease spectrum [16,93]. Moreover, the similarity between the phenotype of
gastric ulcer and gastric cancer raises questions about the carcinogenic potential of the
associated H. pylori strains [93]. Certainly the etiology for H. pylori-associated peptic ulcer in
adults depends on the complex interplay of gastritis phenotype and of progressive physio‐
logical gastro-duodenal alterations through childhood until adulthood, a result of environ‐
mental factors, bacterial virulence factors and host genetic background.
Despite epidemiological evidence that infection during childhood is seldom associated with
peptic ulceration or gastric atrophy, the mechanisms underlying differences in histopathology
and clinical expression of H. pylori infection when compared to the adult, are still poorly
identified. Theoretically, such differences might be explained by qualitative and/or quantita‐
tive differences in induced immune response, possibly age-related. Indeed, adults exhibit a
predominantly neutrophil infiltrate, whereas H. pylori-associated gastritis in children is
usually mild and superficial with a predominantly mononuclear infiltrate, a paucity of
neutrophils and a higher degree of lymphoid follicular hyperplasia [118]. Therefore, different
immunopathology and different patterns of cytokine expression would be anticipated for
children when compared to adults [18]. There may be differences in adaptive component of
gastric mucosa immune response in children compared to the adult host; a clear Th1 response
has not always been demonstrated for young patients. The lower gastritis scores in children
may also be a reflection of such a skewed Th1/Th2 balance, which may result in their lower
risk for developing ulcer disease [18, 19]. These findings could indicate that the host humoral
and cellular responses differ depending on the age at which the gastric infection is first
acquired and might explain the varying rates of disease outcomes that are evident in different
parts of the world. Nevertheless, higher anti-H. pylori IgG antibody titres occur in paediatric
patients with duodenal ulcer compared to those without ulceration, suggesting that local
humoral immune responses contribute to the development of peptic ulceration in these young
patients [102,119,120]. This is not surprising, given the fact that the more severe inflammation,
the greater the chance of ulcer formation [121] with increased IgG production leading to
mucosal damage similar to an Arthus reaction [2].
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1.3.3. Endoscopic features
Endoscopy is the only method to accurately diagnose peptic ulceration in children [87,122]. A
nodular mucosa in the gastric antrum or duodenal bulb and/or gastric or duodenal erosions
or ulcerations are specific (but not sensitive) features, suggesting active H. pylori infection. For
those with suspected infection, biopsies should be obtained for histopathology, as well as
complementary tests for detection of H. pylori including rapid urease test, histopathology with
Giemsa stain and, if available, culture. The rationale for the recommendation to perform more
than one diagnostic test is based on their sensitivity results in children, which range from 66%
to 100% for histology and from 75% to 100% for rapid urease tests [91]. In all paediatric age
groups, for patients receiving therapy with a proton pump inhibitor, biopsies should be
performed on the body and cardia (and, possibly, transition zones) of the stomach as well as
from the antrum to reduce the chances of false-negative results. Follow-up endoscopy is rarely
necessary, except in the setting of peptic ulceration associated with complications (such as
haemorrhage or perforation).
1.3.4. Host susceptibility
The multifactorial nature of peptic ulcer disease reflects its dependence on the patients’ genetic
susceptibility and habits (alcohol and/or non-steroid anti-inflammatory drug consumption,
diet, smoking and stress) [20]. Paediatric peptic ulcer disease is significantly more frequent in
boys than in girls (63.6% versus 36.4%, p<0.025) [32]. Although female hormones may have a
protective role against developing peptic ulcerations [123], the true nature of this susceptibility
of the male gender remains unclear.
Mucins, glycoproteins secreted by the gastric mucosa, form a gel layer that is essential to
maintain a stable neutral pH adjacent to epithelium. This mucus barrier affords protection
from attack by acid-pepsin and other luminal noxious agents [124]. H. pylori has a complex
relationship with different gastric mucins’ subtypes. Infected children for example have a
decreased mucin in their gastric mucosa presumably weakening this important defense barrier
[125]. The highly diverse carbohydrate structure of the gastric mucins, functioning as binding
sites for H. pylori, should also play a role in the outcome of infection, with genetic and epigenetic
changes in the mucin molecules influencing the susceptibility of the patient for H. pylori-
associated peptic ulcer disease. Recently, it was shown that H. pylori-infected children
presented a normal pattern of expression and glycosylation of mucin 5AC (MUC5AC) in the
surface mucous cells, and MUC6 in the gland mucous cells, contrasting with the aberrant
expression of MUC6 and MUC2 found in infected adults. Additionally, it was shown that the
pattern of Lewis blood group antigens in the surface epithelium of children was significantly
correlated with H. pylori load, however no correlation with gastritis, nodularity, and gastric or
duodenal ulcer was found [17].
In children and teenagers, as in adults, the severity of antral inflammation strongly correlates
with the risk of duodenal ulcer disease. Among the host factors, polymorphisms in cytokines
encoding genes, or in their promoters, that affect cytokine transcription, are good risk candi‐
dates. Indeed, polymorphisms in the IL-1 gene cluster play an important role in modulating
the risk for H. pylori-induced hypochlorhydria and, thus, for gastric ulceration and cancer. The
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IL-1 cluster, located on chromosome 2q12-22 region, includes the genes IL-1A, IL-1B and
IL-1RN that code for the proinflammatory cytokines IL-1α, IL-1β and their endogenous
receptor antagonist IL-1RA, respectively. The less common alleles of IL-1B, i.e., IL-1B-31C and
IL-1B-511T (representing, respectively, T-C and C-T transitions at positions 31 and 511 of the
IL-1B promoter) are associated with a higher risk of hypochlorhydria [116]. This association
can be explained considering that such polymorphisms lead to increased IL-1β expression/
secretion that, upon H. pylori-infection, amplifies the host inflammatory response. Also the less
common allele of IL-1RA, i.e., the IL-1RN*2 (representing one of the five known 86 base pair
tandem repeat polymorphisms in intron 2) is associated with a higher risk of gastric cancer in
adults [116]. The risk is potentiated when in association with infection by cagA/vacA-positive
H. pylori strains, highlighting the interplay between host and bacterial factors that seems to be
involved in the development of gastric pathology [126]. Children presenting the IL1RN*2 allele
and infected by cagA-positive H. pylori strains are at higher risk of duodenal ulceration,
emphasizing differences in the physiopathology of the disease between adult and paediatric
patients [124]. Also at higher risk of developing duodenal ulcer are children presenting the
transition G-A at position 238 of the TNF-α coding gene when infected by iceA1-positive H.
pylori strains [127].
Other  putative  host  risk  factors  for  H.  pylori-severe  gastroduodenal  diseases  are  the
polymorphisms in the genes coding for Toll-like receptors (TLRs) that might influence the
innate and adaptive immune response to the infection. Indeed, the presence of the TLR4
allele in combination with infection by cagA-positive strains, leads to increased gastric levels
of IL-8 and IL-10 [128].
1.4. Molecular profile of ulcerogenic paediatric H. pylori strains
The co-evolution between H. pylori and the modern humans has determined the extremely
high diversity of the bacterium in both its genetic background and virulence. Thus, it is likely
that bacterial determinants may influence the clinical outcome, an association that is well
established for cagA, vacA and babA genes (see sections 1.2.2 and 1.2.3 of this chapter). Never‐
theless, this topic is far from being fully clarified, and the identification of other factors
responsible for the enhanced virulence of the bacteria leading to the development of more
severe diseases remains pertinent. For that purpose, the study of H. pylori strains isolated in
specific clinical situations, such as the paediatric peptic ulcer disease, can be useful. Indeed,
H. pylori paediatric infection may be regarded as a privileged natural study model of the
interaction of this bacterium with human host, as the child is usually not exposed to injurious
factors as is the adult and represents a different stage of H. pylori infection in a immunologically
maturing host. Comparative genomic studies of the rare paediatric ulcerogenic H. pylori strains
and of the non-ulcerogenic strains show a distinctive genotype virulence pattern, suggesting
a potential pathogenic role for new markers [9-15]. Two putative virulence determinants are
associated with peptic ulceration, mostly duodenal ulcer, in children and with other H.
pylori-virulence factors: jhp0562, involved in lipopolysaccharide biosynthesis and in the
regulation of Lewis antigen expression [13]; and homB, a putative outer membrane protein,
involved in bacterial adherence [9,11,12,14,15]. HomB contributes to the proinflammatory
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characteristics of H. pylori. Strains that are also positive for both homB and jhp562 are related
to a higher risk of paediatric peptic ulcer disease. Thus, it is likely that these new markers
acting together with the well-established virulence markers will promote a more severe antral
inflammation, a phenomenon strongly associated with duodenal ulceration.
Other pathogenic genes interact synergistically to induce peptic ulcer in young patients. There
is no gene or protein that acts alone to establish the virulence of H. pylori [74]. Accordingly, we
investigated further virulence-associated genes by comparing the proteome of a group of
genetically/epidemiologically-unlinked H. pylori strains, all isolated from Portuguese children,
half suffering with peptic ulcer disease, and the other presenting only active gastritis [16].
Despite the typical proteome profile of all the H. pylori strains grown under the same labora‐
torial conditions [129], the ulcerogenic paediatric H. pylori strains presented differences
suggestive of higher motility, better antioxidant defences and a metabolism favouring the
biosynthesis of aromatic amino acids. As already mentioned in this chapter (see section 1.2.1
of this chapter) motility is a long known virulence-related trait [46], with lower-motility
associated reduced inflammation levels [47] and with non-motile strains unable to establish a
robust infection [42,45,46]. Moreover, it was more recently shown that higher motility enhances
H. pylori density and inflammatory response in dyspeptic patients [130].
The differences in the abundance of antioxidant proteins observed between paediatric
ulcerogenic and non-ulcerogenic strains may be important in conferring resistance to inflam‐
mation; the enzymes involved in key steps in the metabolism of glucose, amino acids and urea
may be advantageous to respond to fluctuations of nutrients [16].
Additionally, by comparing the duodenal ulcer-associated paediatric strains with the one
studied strain associated with gastric ulcer, we observed differences on the abundance of
proteins associated with acid resistance and motility. These suggest that the former are better
prepared to survive to the abnormal low levels of pH observed in duodenal ulceration, in
contrast to the gastric ulcer strain which is a better swimmer, supporting the proximal spread
of infection characteristic of this disease [16]. Overall, our data supports the idea that the
infecting strain may be determinant in the divergence between duodenal and gastric ulcer [93].
2. Conclusions
The prevalence of H. pylori infection remains high worldwide despite a progressive decline
over time, attributed to improved overall living conditions and hygiene. Although often
asymptomatic, most infected patients suffer from persistent non-ulcer dyspepsia that, usually
later in adulthood, may further progress to more severe conditions. The most common severe
complication H. pylori is duodenal ulcer, affecting 10 to 15% of the infected adults. Although
less frequent, 2 to 5% of the infected adults with non-ulcer dyspepsia progress to gastric
ulceration and some ultimately to gastric cancer. These two forms of peptic ulcer-related
(organic) dyspepsia differ in prevalence and physiopathology; those suffering with duodenal
ulcer are at low risk of developing a gastric ulcer/gastric cancer. The onset of peptic ulcers in
childhood is a rare event that may occur shortly after infection, suggesting more virulent H.
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pylori strains and more susceptible young patients. H. pylori-associated paediatric peptic ulcer
disease is, therefore, a privileged natural study model to search for ulcerogenic-specific
bacterial biomarkers and implicated molecular mechanisms, a required step to better address
this important public health problem. This includes enhanced virulence of the paediatric
ulcerogenic H. pylori strains that also may have a natural ability to better adapt to the hostility
of their niche.
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